Zacks Investment Research
15 Jul 2026, 15:55 UTC · 57m ago
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
15 Jul 2026, 15:55 UTC · 57m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Biogen's phase II CELIA study for the Alzheimer's drug diranersen failed to meet its primary endpoint of demonstrating a dose-response relationship. — Failure to meet a primary endpoint in a phase II clinical trial significantly reduces the probability of regulatory approval and future revenue from the drug candidate.
-0.80Higher doses of diranersen produced progressively smaller clinical benefits than the lowest dose (60 mg), creating uncertainty regarding phase III development. — The lack of a clear dose-response relationship complicates the design of late-stage trials and increases the risk of failure in phase III.
-0.60Biogen shares declined 8.2% following the presentation of the CELIA study data at the AAIC. — The immediate price drop reflects the market's negative reaction to the trial results and Biogen's reduced pipeline prospects.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
Shares dropped 8.2% after a phase II study for its Alzheimer's drug failed to meet its primary endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
9h ago
